Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
US Patent Number
8846386
Publication Date
9-30-2014
Abstract
Disclosed herein are nucleic acid molecules comprising a nucleotide sequence of sVEGF-2, proteins encoded by those sequences and antibodies that bind to the protein. Also disclosed are methods for inhibiting or enhancing expression or activity of sVEGFR-2 and methods for inhibiting graft rejection, particularly cornea graph rejection. Also described are methods for inhibiting lymphangiogenesis and lymphatic endothelial cell proliferation by administering an effective amount of sVEGFR-2 and methods for treating lymphedema by inhibiting the activity of sVEGFR-2.
Assignees
University of Kentucky Research Foundation, Lexington, KY (US)
Application Number
12/338,728
Filing Date
12/18/2008
Recommended Citation
Ambati, Jayakrishna and Albuquerque, Romulo J., "sVEGFR-2 and its Role in Lymphangiogenesis Modulation" (2014). Ophthalmology and Visual Science Faculty Patents. 9.
https://uknowledge.uky.edu/ophthalmology_patents/9
